Skip to main content
Top
Published in: Clinical Drug Investigation 7/2013

01-07-2013 | Review Article

Current Topics in Opioid Therapy for Pain Management: Addressing the Problem of Abuse

Authors: Frank E. Casty, Matthew S. Wieman, Neil Shusterman

Published in: Clinical Drug Investigation | Issue 7/2013

Login to get access

Abstract

Opioids are an established therapy for cancer pain and have become an accepted therapy for chronic noncancer pain. However, increased prescribing of opioids in recent years has been accompanied by an increase in prescription opioid abuse. All opioids have inherent potential for abuse, but gaps in healthcare provider understanding of or adherence to best prescribing practices may facilitate the misdirection of opioids for abuse. To address these concerns, the US Food and Drug Administration has required pharmaceutical manufacturers to develop Risk Evaluation and Mitigation Strategies (REMS) for prescribers of extended-release/long-acting (ER/LA) opioids and has encouraged research to develop opioid formulations that are less easily abused or less attractive for abuse. The ER/LA opioid REMS require a partnership between the pharmaceutical industry, regulators, and healthcare providers to develop educational materials for physicians and patients that are not promotional. This article addresses challenges associated with improving the quality of pain care through support of prescriber education, developing formulations that combine efficacy with tamper-resistant properties, and encouraging collaborative efforts by regulatory bodies, legislators, healthcare providers, and patient advocacy groups to achieve these ends.
Literature
2.
go back to reference Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Wkly. 2011;60(43):1487–92. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Wkly. 2011;60(43):1487–92.
5.
go back to reference Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24(2):145–8.PubMedCrossRef Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24(2):145–8.PubMedCrossRef
11.
go back to reference Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8(1):29.PubMedCrossRef Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8(1):29.PubMedCrossRef
14.
go back to reference Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011;7(2):109–15.PubMed Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011;7(2):109–15.PubMed
16.
18.
go back to reference Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11–8.PubMedCrossRef Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11–8.PubMedCrossRef
19.
go back to reference Grudzinskas C, Balster RL, Gorodetzky CW, et al. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006;83(Suppl 1):S77–82.PubMedCrossRef Grudzinskas C, Balster RL, Gorodetzky CW, et al. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006;83(Suppl 1):S77–82.PubMedCrossRef
22.
go back to reference Vosburg SK, Jones JD, Manubay JM, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–15.PubMedCrossRef Vosburg SK, Jones JD, Manubay JM, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–15.PubMedCrossRef
23.
go back to reference OXECTA® (oxycodone HCl, USP). Full prescribing information. Bristol: King Pharmaceuticals; 2011. OXECTA® (oxycodone HCl, USP). Full prescribing information. Bristol: King Pharmaceuticals; 2011.
25.
go back to reference Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777–90.PubMedCrossRef Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777–90.PubMedCrossRef
26.
go back to reference Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manag. 2010;40(5):734–46.CrossRef Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manag. 2010;40(5):734–46.CrossRef
27.
go back to reference Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manag. 2010;39(4):712–20.CrossRef Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manag. 2010;39(4):712–20.CrossRef
30.
go back to reference Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805–10.PubMedCrossRef Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805–10.PubMedCrossRef
34.
go back to reference Black R, Coplan P, Cassidy T, et al. Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network. J Pain. 2012;13(4S):S58. Black R, Coplan P, Cassidy T, et al. Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network. J Pain. 2012;13(4S):S58.
35.
go back to reference Bartholomäus J, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879–91.CrossRef Bartholomäus J, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879–91.CrossRef
36.
go back to reference Rolleri RL, Faulknor J, Schoedel KA, et al. Intranasal abuse potential of immediate-release oxycodone (Acurox®; IROA) formulated to deter abuse. In: College on problems of drug dependence 73rd annual scientific meeting, Hollywood, FL, 18–20 June 2011. Rolleri RL, Faulknor J, Schoedel KA, et al. Intranasal abuse potential of immediate-release oxycodone (Acurox®; IROA) formulated to deter abuse. In: College on problems of drug dependence 73rd annual scientific meeting, Hollywood, FL, 18–20 June 2011.
37.
go back to reference Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9.PubMedCrossRef Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9.PubMedCrossRef
44.
go back to reference Mezei L, Murinson BB, Johns Hopkins Pain Curriculum Development Team. Pain education in North American medical schools. J Pain. 2011;12(12):1199–208.PubMedCrossRef Mezei L, Murinson BB, Johns Hopkins Pain Curriculum Development Team. Pain education in North American medical schools. J Pain. 2011;12(12):1199–208.PubMedCrossRef
45.
go back to reference Wenghofer EF, Wilson L, Kahan M, et al. Survey of Ontario primary care physicians’ experiences with opioid prescribing. Can Fam Physician. 2011;57(3):324–32.PubMed Wenghofer EF, Wilson L, Kahan M, et al. Survey of Ontario primary care physicians’ experiences with opioid prescribing. Can Fam Physician. 2011;57(3):324–32.PubMed
46.
go back to reference Gupta A, Patton C, Diskina D, et al. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors. Pain Physician. 2011;14(4):383–9.PubMed Gupta A, Patton C, Diskina D, et al. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors. Pain Physician. 2011;14(4):383–9.PubMed
49.
go back to reference Leong L, Ninnis J, Slatkin N, et al. Evaluating the impact of pain management (PM) education on physician practice patterns—a continuing medical education (CME) outcomes study. J Cancer Educ. 2010;25(2):224–8.PubMedCrossRef Leong L, Ninnis J, Slatkin N, et al. Evaluating the impact of pain management (PM) education on physician practice patterns—a continuing medical education (CME) outcomes study. J Cancer Educ. 2010;25(2):224–8.PubMedCrossRef
50.
go back to reference Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7(6):467–83.PubMed Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7(6):467–83.PubMed
51.
go back to reference Reuben SS, Connelly NR, Maciolek H. Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg. 1999;88(6):1286–91.PubMed Reuben SS, Connelly NR, Maciolek H. Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg. 1999;88(6):1286–91.PubMed
56.
go back to reference US Fish and Wildlife Service, American Pharmacists Association, Pharmaceutical Research and Manufacturers of America. SMARxT Disposal. A Prescription for a Healthy Planet. 2012. http://www.smarxtdisposal.net/. Accessed 5 Oct 2012. US Fish and Wildlife Service, American Pharmacists Association, Pharmaceutical Research and Manufacturers of America. SMARxT Disposal. A Prescription for a Healthy Planet. 2012. http://​www.​smarxtdisposal.​net/​. Accessed 5 Oct 2012.
Metadata
Title
Current Topics in Opioid Therapy for Pain Management: Addressing the Problem of Abuse
Authors
Frank E. Casty
Matthew S. Wieman
Neil Shusterman
Publication date
01-07-2013
Publisher
Springer International Publishing AG
Published in
Clinical Drug Investigation / Issue 7/2013
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-013-0087-8

Other articles of this Issue 7/2013

Clinical Drug Investigation 7/2013 Go to the issue